论文部分内容阅读
乳腺癌是威胁妇女健康的主要恶性肿瘤之一,随着肿瘤分子生物学研究的发展,分子靶向药物在乳腺癌治疗中取得了一定的疗效,单克隆抗体赫赛汀(Herceptin)是针对乳腺癌Her-2基因的第一个分子靶向药物,为乳腺癌临床治疗带来了突破,但是只有30%的Her-2阳性的乳腺癌患者能从单药中获益,而部分患者可能出现该药物的原发耐药和继发耐药,随着分子靶向药物研究的不断深入,选择
Breast cancer is one of the major malignant tumors that threaten the health of women. With the development of molecular biology of cancer, molecular targeted drugs have achieved some therapeutic effects in the treatment of breast cancer. The monoclonal antibody Herceptin is directed against the breast The first molecular targeted drug for cancer Her-2 gene has brought a breakthrough in the clinical treatment of breast cancer, but only 30% of patients with Her-2 positive breast cancer can benefit from the single drug, while some patients may appear The drug’s primary resistance and secondary drug resistance, with the molecular-oriented drug research continues to choose